ReviewThe Lancet. Infectious diseases2017
Global epidemiology of non-influenza RNA respiratory viruses: data gaps and a growing need for surveillance.
Review in The Lancet. Infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 75 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Can we distinguish respiratory viral infections based on clinical features? A prospective pediatric cohort compared to systematic literature review.Reviews in medical virology · 2018Pooled it
- Long-term impact of the SARS-CoV-2 pandemic on respiratory viruses in Germany.BMC public health · 2025Article
- 'Vivaldi': an amplicon-based whole-genome sequencing method for the four seasonal human coronaviruses, 229E, NL63, OC43 and HKU1, alongside SARS-CoV-2.Microbial genomics · 2025Article
- Computable phenotypes to identify respiratory viral infections in the All of Us research program.Scientific reports · 2025Article
- [Programmed cell death in paramyxovirus infection].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025Review
- Clinical symptoms, comorbidities and health outcomes among outpatients infected with the common cold coronaviruses versus influenza virus.Virology journal · 2024Article
- Resurgence of respiratory syncytial virus infection during COVID-19 pandemic in Pune, India.BMC infectious diseases · 2024Article
- Global Seasonal Activities of Respiratory Syncytial Virus Before the Coronavirus Disease 2019 Pandemic: A Systematic Review.Open forum infectious diseases · 2024Review
- Article
- Longitudinal transcriptome analysis reveals distinct gene expression patterns in traditional Chinese medicine syndromes of upper respiratory tract infections.Frontiers in genetics · 2024Article
- Seasonality of endemic COVID-19.mBio · 2023Article
- Effectiveness of Self-Collected, Ambient Temperature-Preserved Nasal Swabs Compared to Samples Collected by Trained Staff for Genotyping of Respiratory Viruses by Shotgun RNA Sequencing: Comparative Study.JMIR formative research · 2023Article
- Stabilization of the Quadruplex-Forming G-Rich Sequences in the Rhinovirus Genome Inhibits Uncoating-Role of NaViruses · 2023Article
- Respiratory infections and type 1 diabetes: Potential roles in pathogenesis.Reviews in medical virology · 2023Review
- Editorial: High-impact respiratory RNA virus diseases.Frontiers in veterinary science · 2023Article
- Beyond SARS-CoV-2: epidemiological surveillance of respiratory viruses in Jalisco, Mexico.Frontiers in public health · 2023Article
- Etiologies of influenza-like illness and severe acute respiratory infections in Tanzania, 2017-2019.PLOS global public health · 2023Article
- Cardiovascular Complications of Viral Respiratory Infections and COVID-19.Biomedicines · 2022Review
- Epidemiological Patterns of Seasonal Respiratory Viruses during the COVID-19 Pandemic in Madagascar, March 2020-May 2022.Viruses · 2022Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedCorrections.2017
Authors and funding
9 authors.
Funding
Abstract
Together with influenza, the non-influenza RNA respiratory viruses (NIRVs), which include respiratory syncytial virus, parainfluenza viruses, coronavirus, rhinovirus, and human metapneumovirus, represent a considerable global health burden, as recognised by WHO's Battle against Respiratory Viruses initiative. By contrast with influenza viruses, little is known about the contemporaneous global diversity of these viruses, and the relevance of such for development of pharmaceutical interventions. Although far less advanced than for influenza, antiviral drugs and vaccines are in different stages of development for several of these viruses, but no interventions have been licensed. This scarcity of global genetic data represents a substantial knowledge gap and impediment to the eventual licensing of new antiviral drugs and vaccines for NIRVs. Enhanced genetic surveillance will assist and boost research and development into new antiviral drugs and vaccines for these viruses. Additionally, understanding the global diversity of respiratory viruses is also part of emerging disease preparedness, because non-human coronaviruses and paramyxoviruses have been listed as priority concerns in a recent WHO research and development blueprint initiative for emerging infectious diseases. In this Personal View, we explain further the rationale for expanding the genetic database of NIRVs and emphasise the need for greater investment in this area of research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.